BioPharmSignal logoBioPharmSignal

Biotech News

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Adial Pharmaceuticals (ADIL)Adial PharmaceuticalsClinical readout

Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar Market

Glen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage...

Related news

ADILAdial Pharmaceuticals2024-06-05 08:30 EST

Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

ADILAdial Pharmaceuticals2025-06-11 08:00 EST

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

View all latest news

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.

Recent company news

ADILAdial Pharmaceuticals2025-06-11 08:00 EST

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

ADILAdial Pharmaceuticals2025-05-15 08:30 EST

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ADILAdial Pharmaceuticals2025-05-13 08:30 EST

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

ADILAdial Pharmaceuticals2025-05-08 08:30 EST

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

ADILAdial Pharmaceuticals2025-05-02 11:48 EST

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Stock data

Close
4.80 USD
Market cap
5.06M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States